Strata Skin Sciences (SSKN) Earns News Impact Score of 0.07
Media headlines about Strata Skin Sciences (NASDAQ:SSKN) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Strata Skin Sciences earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave news stories about the medical device company an impact score of 47.7242396052783 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Strata Skin Sciences (NASDAQ:SSKN) remained flat at $1.65 during trading on Friday. 11,772 shares of the company traded hands. The company’s market capitalization is $4.09 million. The firm has a 50 day moving average price of $1.85 and a 200-day moving average price of $1.87. Strata Skin Sciences has a 1-year low of $1.43 and a 1-year high of $5.40.
Strata Skin Sciences (NASDAQ:SSKN) last issued its earnings results on Thursday, August 10th. The medical device company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.19. The company had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $7.98 million. Strata Skin Sciences had a negative net margin of 18.00% and a negative return on equity of 41.58%. Equities research analysts predict that Strata Skin Sciences will post ($3.14) EPS for the current fiscal year.
Several analysts recently weighed in on the company. HC Wainwright set a $12.00 price objective on Strata Skin Sciences and gave the company a “buy” rating in a report on Friday, August 11th. ValuEngine raised Strata Skin Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, June 16th. Zacks Investment Research lowered Strata Skin Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. Finally, Rodman & Renshaw boosted their price objective on Strata Skin Sciences from $1.50 to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 16th.
Strata Skin Sciences Company Profile
STRATA Skin Sciences, Inc, formerly MELA Sciences, Inc, is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging.
Receive News & Ratings for Strata Skin Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strata Skin Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.